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Abstract
Elevated cerebrospinal fluid (CSF) levels of the glia-derived N-methyl-D-aspartic acid receptor 
antagonist kynurenic acid (KYNA) have consistently been implicated in schizophrenia and bipolar 
disorder. Here, we conducted a genome-wide association study based on CSF KYNA in bipolar 
disorder and found support for an association with a common variant within 1p21.3. After 
replication in an independent cohort, we linked this genetic variant—associated with reduced 
SNX7 expression—to positive psychotic symptoms and executive function deficits in bipolar 
disorder. A series of post-mortem brain tissue and in vitro experiments suggested SNX7 
downregulation to result in a caspase-8-driven activation of interleukin-1β and a subsequent 
induction of the brain kynurenine pathway. The current study demonstrates the potential of using 
biomarkers in genetic studies of psychiatric disorders, and may help to identify novel drug targets 
in bipolar disorder.
INTRODUCTION
Elevation of brain kynurenic acid (KYNA) is a consistently found biochemical aberration in 
schizophrenia and bipolar disorder (BD).1–7 Brain KYNA is mainly produced in astrocytes 
as an end-metabolite of the kynurenine pathway of tryptophan metabolism. This pathway is 
highly inducible by inflammatory stimuli,8 and we have previously reported that 
cerebrospinal fluid (CSF) levels of the proinflammatory cytokine interleukin (IL)-1β are 
markedly increased in patients with BD or schizophrenia, although the majority of other 
cytokines measured in this study were undetectable.9,10
KYNA is a neuroactive metabolite that antagonizes the glycine co-agonist site of the N-
methyl-D-aspartic acid receptor (NMDAR).8 Administration of synthetic NMDAR 
antagonists causes psychotic symptoms in healthy individuals,11 and exacerbates psychotic 
features in patients with schizophrenia.12 Psychotic symptoms are core features of 
schizophrenia, and more than half of patients with BD will experience psychosis in their 
lifetime.13 Supporting that KYNA might be specifically involved in the pathophysiology 
underlying psychotic symptoms, we have found higher levels of CSF KYNA in BD-I 
patients with a history of psychosis compared with those who had never experienced 
psychosis.14 KYNA also noncompetitively antagonizes the cholinergic α7 nicotinic receptor, 
and animal studies indicate that increased brain KYNA might cause cognitive deficits.8 In 
rats, increased brain KYNA causes behavioral responses analogous to impaired set-shifting 
in humans,15 an index of executive function. Set-shifting dysfunction as measured by the 
trail making test (TMT) is indeed a feature of schizophrenia and euthymic BD,16,17 
especially in BD patients with a history of psychosis.18
Family history is the strongest risk factor for BD, but an important obstacle for progress in 
psychiatric genetics is that psychiatric syndromes—based solely on symptom clustering—do 
not necessarily reflect specific underlying biological dysfunctions and may be insufficient to 
delineate heritable phenotypes.19 Indeed, epidemiological and molecular genetic studies 
have blurred the diagnostic boundary between schizophrenia and BD by demonstrating that 
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these disorders have partly shared genetic causes.20,21 Complementary approaches to 
unearth causal genetic mutations are therefore needed. One approach is to focus on 
biomarkers, that is, measurable key components in biological pathways between genotype 
and disease.22 For this purpose, the use of CSF KYNA may be particularly rewarding given 
its biological links to distinct subdomains of pathology present in both BD and 
schizophrenia.
In this study of euthymic BD patients, we found CSF IL-1β and KYNA to be associated 
with a history of psychosis and set-shifting impairment. CSF levels of KYNA were also 
strongly associated with the dopamine metabolite homovanillic acid (HVA). We conducted a 
genome-wide association study (GWAS) against CSF levels of KYNA in BD that revealed a 
genome-wide significant association with the single-nucleotide polymorphism (SNP) 
rs10158645 within 1p21.3, a finding that was replicated in an independent cohort of BD 
patients. Furthermore, we analyzed this SNP in relation to CSF HVA, a history of psychosis 
(followed by a replication in a large data set of 565 BD patients) and set-shifting ability. As 
the minor allele in rs10158645 was associated with decreased expression of sorting nexin 7 
(SNX7), we attempted to decipher the biochemical chain of events using a multipronged 
approach including causal inference analyses of clinical data, post-mortem data and cell 
culture studies. These experiments converged on the proposal that decreased SNX7 
expression is linked to increased CSF KYNA concentration and ultimately psychosis and 
set-shifting difficulties in BD through caspase-8-driven activation of IL-1β.
MATERIALS AND METHODS
The study was approved by the institutional review board of the Karolinska Institutet. 
Informed consent was obtained from all included subjects.
Clinical data sets (I–IV)
All patient data were collected from Swedish euthymic BD patients in a long-term follow-up 
program. The diagnostic procedure has been outlined in detail previously.3 In addition to the 
collected research data, we also performed medical chart reviews for the patients in data sets 
I, II and III, and in some cases interviews with the treating physician, to assure the 
diagnostic accuracy (see Supplementary Information). If not specified in the Supplementary 
Information, all analyses included all subjects for whom data were available (the numbers 
vary because not all patients volunteered to undertake all investigations). The general 
population controls were randomly selected by Statistics Sweden (except for the controls 
used in the analyses of CSF IL-1β who were healthy volunteers collected at Linköping 
University Hospital in Sweden). Further descriptions of the data sets, as well as details of 
CSF collection and analyses, are provided in the Supplementary Information. The 
Supplementary Information also contains a table describing the main analyses in relation to 
the different cohorts (Supplementary Table S1). Experienced psychologists performed the 
neuropsychological assessments, using Delis–Kaplan Executive Function System. To obtain 
a sensitive measure of set-shifting, we employed TMT of Delis–Kaplan Executive Function 
System and extracted the total time taken for Combined Letter/Number Switching minus the 
Combined Number Sequencing+Letter Sequencing, that is, ‘switching cost’. Raw contrast 
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scores were transformed into age-corrected scaled contrast scores based on normative data in 
which an achievement score of 10 represents the mean in each age group.23
Genotyping and quality control
Whole-genome genotyping in data set II, as well as in controls, was done on the Affymetrix 
6.0 array (Santa Clara, CA, USA) at the Broad Institute in Boston, MA, USA. Subjects in 
sample IV were genome-wide genotyped using the Affymetrix 6.0 chip or the Illumina 
OmniExpress chip (Illumina, Inc., San Diego, CA, USA). Procedures for genotyping and 
quality control have been provided in prior publications.24 Patients in sample III were 
genotyped for rs10158645 on a 7900HT Fast Real-Time PCR System Instrument by using 
allele-specific TaqMan MGB probes labeled with fluorescent dyes FAM and VIC (Applied 
Biosystems, Foster City, CA, USA) according to the manufacturer’s protocols. Allelic 
discrimination was performed with the ABI PRISM 7900HT SDS and the SDS 2.2.1 
program (Applied Biosystems) in 384-well format with 9 negative controls distributed in 
each plate. The rs10158645 genotype distribution did not depart from Hardy–Weinberg 
equilibrium. Ten percent of the samples were run in duplicate to verify genotyping results.
Expression quantitative trait data and coexpression patterns (data sets V–IX)
Data set V was based on fibroblast data from the MuTHER resource and assessed through 
the Genevar database (GENe Expression VARiation, The Wellcome Trust Sanger Institute; 
http://www.sanger.ac.uk/resources/software/genevar). The replication data set (VI) was 
based on lymphoblastoid cell lines from all unrelated subjects of the HapMap3 population 
(SNPexp v1.2; http://app3.titan.uio.no/biotools/help.php?app=snpexp). For the lncRNA 
(RP5-896L10.1) and SNX7 coexpression analysis (data set VII), we used a sample from the 
Functional Genomics Laboratory at University of California, Irvine (MPV) in which RNA-
sequencing analyses for both coding and noncoding transcripts were assayed from 32 
dorsolateral prefrontal cortex samples obtained from healthy volunteers. To study 
coexpression of SNX7, CASP8, IL1B and TDO2 (data set VIII), we used a post-mortem 
brain tissue collection deposited in the Braincloud database (http://braincloud.jhmi.edu). 
Through an authorized access (MPV), we obtained data on 272 tissue homogenates of 
dorsolateral prefrontal cortex gray matter (BA46/9) from healthy donors. The sample and the 
methods have been previously described.25 Levels of dorsolateral prefrontal cortex (BA46) 
CASP8 mRNA in relation to psychosis in BD (data set IX) were studied using data obtained 
from the Stanley Medical Research Institute database (www.stanleygenomics.org).
Human astrocyte cultures
Human embryonic primary cortical astrocytes were purchased from ScienCell Research 
Laboratories (Carlsbad, CA, USA) and cultured according to the manufacturer’s 
recommendations. Before experiments, characterization of the cells was performed to rule 
out the presence of microglia or neurons in the culture. All experiments were performed on 
cells in passage 4. Cells were serum starved (0.02% fetal bovine serum and 0.01% growth 
supplement mix) for 24 h before experiments. Cytokines and antibodies used in the cell 
studies are described in the Supplementary Information.
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Quantitative real-time PCR
Total RNA was extracted using Trizol Reagent (Invitrogen, Carlsbad, CA, USA) according 
to the manufacturer’s protocol. Quantitative PCR was performed using the Fast Real-Time 
PCR System (Applied Biosystems). See Supplementary Information for a complete 
description of used methods.
Western blot analyses
Total protein was extracted using ice-cold lysis buffer. The membrane was incubated with 
primary antibody against tryptophan 2,3-dioxygenase-2 (TDO2; 1:2000) or indoleamine 2,3-
dioxygenase 1 (IDO1; 1:1000) overnight, and then incubated with secondary antibody for 1 
h in room temperature. Protein levels were normalized to β-actin (1:5000) and blots were 
analyzed using Quantity One 1-D Analysis Software (Bio-Rad, Hercules, CA, USA). See 
Supplementary Information for further details.
Analysis of KYNA in cell culture supernatants
Cell culture supernatants were collected and immediately frozen on dry ice and kept in 
− 20 °C until analysis. Analyses of KYNA are described in Supplementary Information.
Statistics
The primary analysis in the GWAS was a linear regression of CSF KYNA residuals on 
single-SNP allele dosage. ‘Genome-wide significance’ was set to P<5 × 10−8. Additional 
analyses with the first four multidimensional scaling components as covariates to control for 
population substructure were also performed. In the correlation analyses, ‘r’ refers to 
Pearson’s correlation coefficient if not otherwise specified. The sample size chosen in the 
replication of the GWAS was based on a power of 95%. The assumptions of each test were 
checked. All reported P-values are two sided. All analyses were done using the statistical 
software programs R (R Development Core Team, Vienna, Austria), IBM SPSS Statistics 
20.0 (IBM SPSS, Chicago, IL, USA), the script PROCESS for SPSS (percentile bootstrap = 
20 000) and Graph-Pad prism 6.0 (http://www.graphpad.com/).
RESULTS
CSF biomarkers and clinical endophenotypes in BD
CSF IL-1β concentrations in male euthymic BD patients (N = 27) were derived from data 
set I. Patients with a history of psychosis (N = 16) had significantly increased CSF IL-1β 
concentrations compared with patients without (N = 11), but both groups displayed 
increased IL-1β levels compared with healthy controls (N = 30; Figure 1a). The control 
group was significantly younger than the patient groups but CSF IL-1β concentration was 
not associated with age, and adjusted analyses gave similar results (data not shown). Body 
mass index, smoking status and weekly alcohol consumption were also independent of CSF 
IL-1β concentration (data not shown). Comparison of pharmacological treatments between 
psychotic and nonpsychotic bipolar patients suggested an equal distribution (Supplementary 
Table S2), and no significant effects of any pharmacological treatment on IL-1β 
concentration could be detected (data not shown).
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In conjunction with the lumbar puncture, 16 of the 27 BD patients volunteered for cognitive 
testing with TMT to evaluate executive functions in terms of set-shifting ability. The median 
CSF IL-1β concentration was significantly higher in patients who scored below the mean 
standard score of 10 on TMT (Switching vs Combined Number Letter Sequencing) 
compared with patients scoring ≥ 10 (Figure 1b). As a putative influx of peripheral IL-1β to 
the brain may influence central levels of IL-1β, we tested for a possible confounding effect 
of peripheral inflammation by measuring serum high-sensitivity C-reactive protein in these 
patients. High-sensitivity C-reactive protein covaries with serum concentration of IL-1β,26 
and is associated with cognitive impairment.27 Nevertheless, a significant negative 
correlation between CSF IL-1β concentration and set-shifting ability remained, even after a 
partial correlation analyses with high-sensitivity C-reactive protein as covariate (Figure 1c).
We measured CSF KYNA concentrations in a cohort of genotyped euthymic BD patients (N 
= 76, data set II) and randomly selected controls from the general population (N = 46). An 
effect of age on CSF KYNA concentration was observed in patients as well as in controls (β 
(unstandardized coefficient) = 0.025, P = 2 × 10−3, β = 0.031, P = 7 × 10−6, respectively). 
To account for potential age confounding, we henceforth used the residuals from a linear 
regression of age vs CSF KYNA when age was indicated as a potential confounder. In 
patients, CSF KYNA concentration was independent of bipolar subtype (P = 0.63). Nor did 
age-adjusted CSF KYNA concentration correlate to lifetime number of mood episodes (P = 
0.54), body mass index, smoking status or weekly alcohol consumption (data not shown). 
The 36 patients with a history of psychosis but not the 40 patients without such a history had 
a significantly increased mean CSF KYNA concentration compared with the control group. 
Moreover, patients with a history of psychosis had significantly higher CSF KYNA 
concentration than patients without a history of psychosis (Figure 2a). Comparing 
pharmacological treatments between these groups, only lithium use was more common in 
the group with a history of psychosis (Fisher’s exact test; P = 0.034). However, the use of 
lithium was not associated with CSF KYNA concentration (P = 0.75). For a complete list of 
ongoing pharmacological treatments in data set II, see Supplementary Table S3.
Of the 76 euthymic bipolar patients in data set II, 51 volunteered for cognitive testing with 
TMT. In line with the findings regarding IL-1β, the mean CSF KYNA concentration was 
significantly higher in patients who scored <10 (N = 26) compared with patients scoring ≥ 
10 (N = 25; Figure 2b). Comparison of pharmacological treatments between the groups 
suggested an equal distribution (data not shown).
CSF concentration of HVA was successfully determined in 72 of the 76 patients in data set II 
and in 45 of the 46 controls. A strong positive correlation to CSF KYNA was observed in 
patients (Figure 2c). Similar to the analysis of CSF KYNA, patients with a history of 
psychosis had a significantly higher mean CSF HVA concentration than healthy controls or 
nonpsychotic BD patients, where no significant difference in CSF HVA concentration was 
seen (Figure 2d).
Common genetic variants and CSF biomarkers in BD
To elucidate the genetic variability underlying individual levels of CSF KYNA in BD, we 
conducted a GWAS against CSF KYNA concentrations using data set II. Despite the modest 
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sample size (N = 76), one SNP (rs10158645), located within 1p21.3, reached genome-wide 
statistical significance in relation to CSF KYNA (β = 1.07, r = 0.58, P = 2.6 × 10−8, minor 
allele frequency = 0.15; Supplementary Figure S1A (MH-plot), Supplementary Figure S1B 
(QQ-plot), Supplementary Figures S1C–E). Background characteristics were similar 
between carriers and noncarriers of the minor allele in rs10158645 (Supplementary Table 
S4). Neither the total number of mood episodes nor the number of depressive episodes were 
associated with rs10158645 genotype (data not shown). To control for population 
substructure, we also analyzed the association using the first four multidimensional scaling 
components as covariates. In line with a low grade of genetic diversity (all subjects and their 
parents were born in Sweden), this yielded a similar result as the unadjusted analysis (β = 
1.08, P = 4.3 × 10−8; for multidimensional scaling plots see Supplementary Figures S2A and 
B.
We then measured CSF concentrations of KYNA and genotyped rs10158645 (minor allele 
frequency = 0.15) in an independent cohort of 18 female and 12 male Swedish BD patients 
(data set III; median age 39 years, interquartile range = 22). In this data set, 13 patients had a 
BD-I diagnosis and 17 a BD-II diagnosis. Similar to the analysis in data set II, we observed 
a strong positive correlation between the minor G allele in rs10158645 and CSF KYNA 
concentration (Table 1 and Supplementary Figure S3).
Analogous to results in BD patients, a significant effect of the minor G allele of rs10158645 
on CSF KYNA concentration was also seen in the 46 healthy controls (β = 0.43, r = 0.31, P 
= 0.036; Supplementary Figure S4), although none of the controls carried the G/G genotype. 
Including an adjustment for population stratification gave a similar result (β = 0.50, P = 
0.021). The allele distribution in rs10158645 did not differ when comparing all BD patients 
with controls (N = 123, odds ratio = 1.60, 95% confidence interval: 0.68–3.72; P = 0.30), but 
the risk allele was significantly overrepresented in bipolar subjects with psychosis compared 
with controls (N = 83, odds ratio = 2.83, 95% confidence interval: 1.10–7.23; P = 0.031).
Follow-up studies of rs10158645: psychosis and set-shifting ability
The minor allele of rs10158645 was associated with psychotic symptoms in data set II (odds 
ratio = 3.98, P = 0.011; Table 1). We then studied the effect of rs1018645 genotype on 
psychosis using an independent data set of 565 BD patients without CSF data (data set IV). 
Again, we tested the effect of the rs10158645 genotype on risk of psychosis and observed an 
increased risk of psychosis for patients carrying the minor G allele (odds ratio = 1.50, P = 
0.020; Table 1).
To achieve sufficient power, we tested the effect of rs10158645 on set-shifting ability 
combining all patients in data sets II and IV with TMT data (N = 89). Carriers of the minor 
allele scored lower than the mean standard score of 10 (N = 29, M = 8.93 ± 0.47), whereas 
noncarriers scored close to 10 (N = 60, M = 10.1 ± 0.30; P = 0.035), indicating diminished 
cognitive flexibility in carriers of the minor allele.
Causal mediation analyses
The minor allele in rs10158645 was associated with increased CSF HVA concentration in 
data set II (β = 0.54, P = 7.3 × 10−7; Table 1). As previous experimental studies showed that 
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elevation of rat brain KYNA levels is associated with activation of midbrain dopamine 
firing,28 we applied a statistical mediational model with rs10158645 allele frequency as the 
causal variable, CSF KYNA as the mediator and CSF HVA as the outcome variable. The 
same cases (N = 72) were used in all analyses, and the same covariate (age) were used in all 
equations. Using a nonparametric bootstrap method,29 the indirect effect that estimates the 
amount of mediation was significant, whereas the direct effect was smaller and 
nonsignificant (Table 1). To study possible reverse causal effects we interchanged the 
mediator and outcome variable. This also suggested a significant indirect effect but now with 
a significant and larger direct effect, hereby suggesting a better fit of the first model. Thus, 
these mediation analyses propose that the causal minor allele in rs10158645 increases CSF 
HVA via KYNA, in agreement with previous experimental studies.
To study whether the association of KYNA on psychosis in BD was driven by an effect on 
dopaminergic transmission, we tested a mediation model in which CSF KYNA was the 
causal variable, CSF HVA the mediator and psychosis the outcome variable. Again, we 
included age as a covariate, and used the same 72 subjects. This model gave a significant 
indirect effect with a nonsignificant direct effect (Table 1), suggesting that the increased risk 
of psychosis caused by elevated levels of KYNA was mediated by dopamine 
neurotransmission.
The identified genetic locus and variation in gene expression
We searched the MuTHER resource30 (fibroblast data, data set V) regarding the effect of 
rs10158645 genotype on gene expression (the search by default set to a search of +/− 1 Mb, 
that is, cis-effects). The strongest association was found between the minor allele in 
rs10158645 and a decreased expression of the nearby gene SNX7 (P = 2.0 × 10−4). We then 
studied the effect of rs10158645 genotype on SNX7 expression in a replication data set (N = 
198, data set VI), based on data from another cell type (lymphoblastoid cell lines) and again 
observed a significant and similar association (P = 9.6 × 10−3).
rs10158645 is located in an intron of RP5-896L10.1, a long noncoding RNA (lncRNA) gene 
that is predominately expressed in the brain, and ~ 2 kB from a predicted enhancer region. 
Although sparsely studied, lncRNA has recently been shown to regulate the expression of 
nearby genes, that is, cis-effects.31 Utilizing tissue from 32 post-mortem human brains (data 
set VII), we found an inverse coexpression of RP5-896L10.1 and SNX7 (r = − 0.23; P = 
0.030), suggesting that the observed cis-effect of rs10158645 on SNX7 was mediated by 
increased RP5-896L10 expression. Against this background, we deemed that the most likely 
functionality of the identified locus was to regulate SNX7 expression.
SNX7 downstream signaling and KYNA synthesis
The SNX family proteins function in diverse intracellular trafficking and signaling 
processes.32 Although SNX7 is rarely studied, a recent report showed that a downregulation 
of SNX7 increases caspase-8 protein levels in hepatocytes, most likely by inducing the 
degradation of the short form of c-FLIP at the riboptosome platform.33 Caspase-8 has a 
pivotal role for microglia activation by cleaving pro-IL-1β into its biologically active 
structure,34,35 and the brain kynurenine pathway almost exclusively plays out in microglia 
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and astrocytes. The first step of the pathway, that is, the conversion of tryptophan to N-
formylkynurenine by the enzyme IDO1 or the complementary enzyme TDO2, are proposed 
to be critically regulated by immune signaling.8
First, we investigated whether IL-1β induces TDO2 and/or IDO1 in human astrocytes, the 
main producer of KYNA in the brain. Stimulation with IL-1β increased the expression of 
both IDO1 and TDO2 mRNA, but only increased protein levels of TDO2. Cells stimulated 
with IL-1β also showed 4 times higher KYNA concentrations compared with vehicle-treated 
cells (see Figure 3 and Supplementary Figures S5–S9 for details). Our results, suggesting 
IL-1β-driven TDO2 upregulation to increase KYNA synthesis, are in line with a recent 
report showing a similar mechanism in human endometrioma stromal cells.36
We performed analyses of human brain mRNA coexpression data to further evaluate the 
importance of SNX7 downregulation for IL-1β-driven induction of TDO2. In a sample of 
272 tissue homogenates of prefrontal gray matter from healthy donors (data set VIII), we 
observed a strong inverse correlation between SNX7 and TDO2 expression (r = − 0.56; P = 
1 × 10−23; Supplementary Figure S10A). In concordance with previous results from 
hepatocytes, we further found a strong inverse coexpression of SNX7 and CASP8 (r = 
− 0.44; P = 2 × 10−14; Supplementary Figure S10B). Notably, we also found that CASP8 
expression was significantly increased in BD with psychotic features compared with BD 
without psychotic features (fold change = 1.15; 99% confidence interval: 1.04–1.20) using 
mRNA expression in a post-mortem sample of 105 BD patients (data set IX). Furthermore, 
consistent with our in vitro data from human astrocytes, we observed a strong correlation 
between IL-1β and TDO2 expression (r = 0.44; P = 5 × 10−14; Supplementary Figure S10C). 
This accords previous studies showing that TDO2 mRNA and protein levels are increased in 
schizophrenia and in BD patients with psychotic symptoms, whereas IDO1 levels are 
unaltered.37
DISCUSSION
This is to the best of our knowledge the first study of a heritable psychiatric disorder that at a 
molecular level attempts to link a GWAS finding, biochemical aberrations and clinical 
presentation. Our results suggest that a risk allele within 1p21.3 gives rise to a series of 
immune-related cascades that elevate brain KYNA levels and contribute to psychotic 
symptoms as well as persistent executive function deficits in BD. Our results align with 
previous experimental and clinical studies suggesting that KYNA, sharing both 
pharmacological and neurobehavioral effects with ketamine and phencyclidine, induces 
psychotomimetic effects and cognitive deficits.1,2,8
The role of KYNA in psychosis converges with multiple lines of evidence implicating an 
increased dopaminergic drive in mania and psychosis.38 Experimental studies have shown 
that elevation of rat brain KYNA levels with the same order of magnitude as observed in BD 
is associated with increased firing of midbrain dopaminergic neurons.28,39,40 These 
experimental findings corroborate our present results, showing higher levels of CSF HVA in 
psychotic BD patients compared with nonpsychotic BD patients, as well as a positive 
correlation between CSF KYNA and HVA. The KYNA-driven activation of dopamine 
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transmission, also supported by our statistical causal mediation analyses, validates the 
classical view that dopamine contributes to psychotic symptoms in BD.
Persistent cognitive impairment is increasingly recognized as an important and heritable 
feature of BD.41 NMDAR as well as cholinergic α7 nicotinic receptor have an established 
role in cognitive functions.15,42,43 The present study demonstrates for the first time in 
humans that KYNA, an endogenous antagonist at both receptors, is associated with impaired 
cognitive flexibility in terms of decreased set-shifting ability. In support of a more 
generalized action of brain KYNA, cognitive enhancers such as D-serine/glycine transporter 
inhibitors or galantamine target the glycine site of the NMDAR or the cholinergic α7 
nicotinic receptor, respectively. Indeed, mice with reduced glycine affinity of the NMDAR 
display behavioral set-shifting impairments that can be reversed by D-serine,43 and blockade 
of glycine transporters promotes set-shifting tasks in rats.44 In addition, KYNA-induced 
impairment in set-shifting ability in rats is reversed by galantamine.15 This suggests that D-
serine/glycine transporter inhibitors or galantamine might prove principally useful to 
counteract cognitive dysfunction associated with high levels of KYNA.
In the present study, the genetic variation within 1p21.3 was also associated with increased 
risk of psychosis and cognitive impairments in BD. Gene expression data suggested that this 
genetic risk allele results in decreased expression of the SNX7. Our post-mortem and in 
vitro data point toward a caspase-8-driven activation of IL-1β that, through TDO2 induction, 
increases the astrocytic production of KYNA, eventually giving rise to psychotic symptoms 
and cognitive dysfunction in BD (Figure 4). It remains to be investigated whether this 
pertains to BD only or is a phenomenon shared with other psychiatric disorders. Clearly, glia 
plays an important role in a broad range of central nervous system pathologies,45,46 and 
under several of these conditions a dysregulation of the kynurenine pathway has been 
observed.8
This study has some important limitations. First, as we use high-resolution phenotypic data, 
for example, CSF biomarkers from a meticulously clinically characterized BD cohort with a 
low grade of genetic diversity, our sample sizes are inevitably much smaller than in 
conventional psychiatric multicenter case–control GWAS. However, the successful 
replications, together with the results of the complementary cell and post-mortem 
experiments, suggest that our findings in the discovery cohort are robust. Moreover, it has 
been repeatedly shown that biomarkers, in comparison with clusters of co-occurring 
symptoms, are under more direct genetic control, and thus more tractable traits in GWAS 
paradigms.47–49 Hence, genetic studies of biomarkers might be an alternative strategy for 
highly needed mechanistic studies of neuropsychiatric disorders, and the current study 
demonstrates the potential of such an approach. Second, although we demonstrate several 
consistent associations between molecular and clinical components, we lack conclusive data 
that directly tie together these individual associations to a signaling pathway that is causally 
related to psychosis and cognitive deficits. More specifically, we do not demonstrate a direct 
link between the genetic risk variant and CSF IL-β levels or between CSF levels of IL-1β 
and KYNA. Third, the analyses of SNX7 downstream signaling were performed on post-
mortem tissue or using in vitro data. Studies using genetic editing in living brain cells are 
warranted to verify these mechanisms.
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To conclude, this study offers evidence for a genetic risk allele that contributes to 
vulnerability for psychosis and cognitive deficits in BD through increased KYNA 
production. The proposed mechanism of an aberrant SNX7/caspase-8/IL-1β signaling, the 
induction of TDO2 enzyme activity and eventually enhanced KYNA synthesis may help to 
identify novel drug targets for the prevention of psychotic symptoms and cognitive 
dysfunction in BD.
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Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Cerebrospinal fluid (CSF) concentrations of interleukin-1β (IL-1β) in male euthymic 
bipolar disorder patients (data set I) and healthy controls. (a) Mean CSF IL-1β concentration 
(± s.e.m.) in 30 healthy male volunteers (0.79 ±0.044 pg ml−1), 16 bipolar disorder patients 
without a history of psychosis (3.06 ± 0.58 pg ml−1) and 11 bipolar patients with a history of 
psychosis 5.35 ± 0.71 pg ml−1. One-way analysis of variance (ANOVA) with Tukey’s post 
hoc tests, P<1 × 10−6; post hoc tests: controls vs nonpsychotic bipolar patients, P = 6 × 10−5; 
controls vs psychotic bipolar patients, P<1 × 10−6; and nonpsychotic bipolar vs psychotic 
bipolar patients, P = 0.020. (b) Of these patients, 16 carried out the trail making test (TMT). 
Nine patients scored ≥ 10 (mean standard score) and 7 scored <10. The median CSF IL-1β 
concentration was higher in the group with more difficulties in set-shifting (5.84 ± 2.89 pg 
ml−1 (median ± interquartile range)) compared with the group that scored ≥ 10 (1.96 ± 2.68 
pg ml−1, Mann–Whitney U-test, P = 0.012). (c) A possible confounding effect of peripheral 
inflammation was assessed with correlation analyses. Increasing CSF IL-1β concentration 
was associated with difficulties in set-shifting (rs (Spearman) = − 0.53, P = 0.034), also 
when adjusting for high-sensitivity C-reactive protein (hsCRP) concentration (rs = − 0.59, P 
= 0.021). Error bars represent mean ± s.e.m. in (a) and in (b) median with third quartile. 
Two-sided P-values, statistical significance set to P<0.05. *P<0.05, ****P<0.0001.
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Figure 2. 
Cerebrospinal fluid (CSF) concentrations of kynurenic acid (KYNA) in euthymic bipolar 
disorder (BD) patients (data set II) and healthy controls. (a) Mean CSF KYNA concentration 
(± s.e.m.) in 46 healthy controls (1.60 ±0.10 nM), 40 bipolar patients without a history of 
psychosis (1.72 ± 0.12 nM) and 36 bipolar patients with a history of psychosis (2.08 ± 0.18 
nM). One-way analysis of variance (ANOVA) with Tukey’s post hoc tests (using residuals 
from a linear regression of age vs CSF KYNA); P = 9 × 10−3; post hoc tests: controls vs 
nonpsychotic bipolar patients, P = 0.99; controls vs psychotic bipolar patients, P = 0.015; 
and nonpsychotic bipolar vs psychotic bipolar patients, P = 0.026. (b) CSF KYNA (nM) in 
the 51 bipolar patients who underwent trail making test (TMT) from Delis–Kaplan 
Executive Function System (D-KEFS). The mean CSF KYNA concentration was 
significantly higher in patients who scored below the mean standard score (<10, N = 26; 
2.12 ± 0.12 nM) compared with patients scoring average or higher (≥10, N = 25; 1.62 ± 0.21 
nM, t-test: P = 0.048, Pearson’s r = 0.28; P = 0.045). (c) The correlation between CSF 
KYNA and CSF homovanillic acid (HVA) (nM) in 72 of these 76 patients. Pearson’s r = 
0.67; P = 9 × 10−11. (d) CSF HVA (nM) concentration in 72 bipolar patients with or without 
a history of psychosis in comparison with CSH HVA levels in 45 healthy controls. One-way 
ANOVA followed by Tukey’s post hoc tests revealed that the psychotic group had a 
significantly higher mean CSF HVA concentration (280 ± 14.4 nM) compared with controls 
(216 ± 10.6 nM, P = 3 × 10−3) and nonpsychotic patients (227 ± 15.6 nM, P = 0.024), 
whereas no significant different in CSF HVA concentration was seen between controls and 
nonpsychotic patients (P = 0.81). CSF KYNA concentration was independent of BD subtype 
(BD-I: M = 1.97 ± 0.17 nM, N = 40; BD-II: M = 1.80 ± 0.13 nM, N = 36, P = 0.43), and did 
not differ by sex (M = 1.93 ± 0.15 nM among females (N = 46), and M = 1.82 ± 0.15 nM 
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among males (N = 30), respectively, P = 0.63). All error bars represent s.e.m. Two-sided P-
values, statistical significance set to P<0.05. *P<0.05, **P<0.01, NS, not significant.
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Figure 3. 
Stimulation of fetal human cortical astrocytes with interleukin-1β (IL-1β) and interferon-γ 
(IFN-γ). Fetal cultured human cortical astrocytes stimulated with recombinant human IL-1β 
(10 ng ml−1) and IFN-γ (200 ng ml−1), a prototypical indoleamine 2,3-dioxygenase 1 
(IDO1) activator, as positive control. Protein levels of IDO1 and tryptophan 2,3-
dioxygenase-2 (TDO2) analyzed at baseline and after exposure to IL-1β or IFN-γ for 48 h. 
IDO and TDO immunopositive bands are normalized to β-actin. Bar graphs here represent 
IDO1 and TDO2 protein levels expressed as % of vehicle-treated control cultures. All cells 
were analyzed for kynurenic acid (KYNA) at time points 1, 3 and 24 h. Bar graphs here 
represent % of vehicle (t = 1 h) at these time points. All data are reported as mean ± s.e.m. 
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All experiments were performed in triplicate and repeated twice. Representative western 
blots of IDO1 and TDO2 are shown below each bar graph (see Supplementary Figures S7–
S9 for full size western blots). (a) Low levels of IDO1 protein expression were detected in 
unstimulated cells, but despite the marked increase of IDO1 mRNA levels following IL-1β 
stimulation, no changes in protein levels were observed after 48 h of IL-1β exposure (90 
± 5.13% vs 100 ± 7.85%, P = 0.41). Stimulation with IFN-γ was associated with a marked 
increase in protein levels of IDO1 (1084 ± 117% vs 100 ± 7.85%, P = 0.001). (b) 
Stimulation with IL-1β for 48 h increased protein levels of TDO2 compared with vehicle-
treated cells (139 ± 11.1% vs 100 ± 2.70%, P = 0.006), whereas stimulation with IFN-γ did 
not affect protein levels of TDO2 (90 ± 11.2% vs 100 ± 8.70% P = 0.21). 
Immunofluorescent staining of IDO1 (c) protein visualized in green and TDO2 (d) protein 
visualized in red following 48 h of IL-1β stimulation confirmed low levels of IDO protein in 
most cells and scattered cells expressing high levels of TDO2. Images captured at × 40 
magnification. Nuclear staining was performed using 4′,6-diamidino-2-phenylindole 
(DAPI). (e) At 24 h, cells stimulated with IFN-γ had more than 85 times higher KYNA 
concentrations (10.8 ± 0.34 nM) than vehicle-treated cells (0.14 ± 0.04 nM, P<0.0001). (f) 
At 24 h, cells stimulated with IL-1β showed 4 times higher KYNA concentrations (mean ± 
s.e.m.: 1.70 ± 0.11 nM) than vehicle-treated cells (0.42 ± 0.10 nM, p<0.0001). Two-sided P-
values, statistical significance set to P<0.05, **P<0.01, ***P<0.001.
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Figure 4. 
Overview of the proposed sorting nexin 7 (SNX7)-mediated induction of the kynurenine 
pathway in bipolar disorder (BD). Downregulation of SNX7 induces the degradation of the 
short form of c-FLIP that competitively inhibits the autocatalytic processing of pro-
caspase-8 at the ripoptosome. This leads to increased levels of active caspase-8, resulting in 
the processing and secretion of interleukin-1β (IL-1β). IL-1β subsequently induces the rate-
limiting enzyme tryptophan 2,3-dioxygenase-2 (TDO2) in the kynurenine pathway, causing 
an elevation in brain kynurenic acid (KYNA) that, according to our clinical association data, 
leads to a persistent set-shifting impairment as well as to a dopaminergic dysregulation that 
evoke vulnerability for psychosis in bipolar disorder.
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